Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2024;30(4):1005-1008. Published online May 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0394

View: 1912 Download: 68

Correspondence to editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging”

Haeryoung Kim, Dong Ho Lee, Yoon Jung Hwang

Clin Mol Hepatol. 2024;30(4):992-993. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0624

View: 1454 Download: 44 Crossref: 1

Letter to the Editor

Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li

Clin Mol Hepatol. 2024;30(4):965-969. Published online June 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0386

View: 2466 Download: 92

Original Article

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2024;30(4):807-823. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0333 Correction in: Clin Mol Hepatol 2025;31(2):669

View: 5749 Download: 342 Web of Science: 12 Crossref: 6

Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B

Gi-Ae Kim, Seung Won Choi, Seungbong Han, Young-Suk Lim

Clin Mol Hepatol. 2024;30(4):793-806. Published online July 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0252

View: 3228 Download: 216 Web of Science: 9 Crossref: 10

UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL

Renyu Zhang, Can Li, Shuai Zhang, Lingmin Kong, Zekun Liu, Yixiao Guo, Ying Sun, Cong Zhang, Yule Yong, Jianjun Lv, Meng Lu, Man Liu, Dong Wu, Tianjiao Zhang, Haijiao Yang, Ding Wei, Zhinan Chen, Huijie Bian

Clin Mol Hepatol. 2024;30(4):771-792. Published online June 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0236

View: 3317 Download: 324 Web of Science: 6 Crossref: 7

Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting

Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du

Clin Mol Hepatol. 2024;30(4):735-755. Published online May 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0058

View: 4425 Download: 370 Web of Science: 8 Crossref: 11

Editorial

Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”

Paul Y. Kwo

Clin Mol Hepatol. 2024;30(4):714-717. Published online June 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0425

View: 2091 Download: 71 Web of Science: 2 Crossref: 2

Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”

Junlong Dai, Jimmy Che-To Lai, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2024;30(4):698-701. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0327

View: 2074 Download: 57 Web of Science: 2 Crossref: 3

Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”

Joseph C. Ahn, Ju Dong Yang

Clin Mol Hepatol. 2024;30(4):689-691. Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0348

View: 2011 Download: 47 Web of Science: 1 Crossref: 1

Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Naoshi Nishida

Clin Mol Hepatol. 2024;30(4):682-688. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0324

View: 2974 Download: 112 Crossref: 1

Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”

Seren M. Gedallovich, Paul Y. Kwo

Clin Mol Hepatol. 2024;30(4):677-681. Published online June 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0418

View: 1817 Download: 38

Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”

Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon

Clin Mol Hepatol. 2024;30(4):659-662. Published online July 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0516

View: 1703 Download: 87

Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging”

Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang

Clin Mol Hepatol. 2024;30(4):653-655. Published online July 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0482

View: 2018 Download: 70 Web of Science: 2

Original Article

Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy

Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Hsing-Tao Kuo, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Cheng-Yuan Peng, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Jia-Horng Kao, Chun-Jen Liu, Chen-Hua Liu, Sheng-Lei Yan, Chun-Yen Lin, Wei-Wen Su, Cheng-Hsin Chu, Chih-Jen Chen, Shui-Yi Tung, Chi‐Ming Tai, Chih-Wen Lin, Ching-Chu Lo, Pin-Nan Cheng, Yen-Cheng Chiu, Chia-Chi Wang, Jin-Shiung Cheng, Wei-Lun Tsai, Han-Chieh Lin, Yi-Hsiang Huang, Chi-Yi Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chung, Ming-Jong Bair, Ming-Lung Yu, T-COACH Study Group

Clin Mol Hepatol. 2024;30(3):468-486. Published online April 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0038

View: 4987 Download: 205 Web of Science: 9 Crossref: 5

Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George

Clin Mol Hepatol. 2024;30(3):436-448. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0109

View: 8135 Download: 351 Web of Science: 20 Crossref: 21

Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma

Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, Chi-Jen Chu, Yi-Hsiang Huang, Teh-Ia Huo, Yu-Hui Su, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su

Clin Mol Hepatol. 2024;30(3):406-420. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0103

View: 4631 Download: 219 Web of Science: 11 Crossref: 12

Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma

Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim

Clin Mol Hepatol. 2024;30(3):360-374. Published online March 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0042

View: 5997 Download: 366 Web of Science: 3 Crossref: 4

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study

Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2024;30(3):345-359. Published online March 12, 2024

DOI: https://doi.org/10.3350/cmh.2023.0553

View: 5717 Download: 471 Web of Science: 15 Crossref: 12

Letter to the Editor

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 3642 Download: 150 Web of Science: 11 Crossref: 11

Editorial

Steatotic liver disease: Know your enemies

Lung-Yi Mak

Clin Mol Hepatol. 2024;30(2):171-173. Published online February 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0078

View: 3187 Download: 99 Web of Science: 3 Crossref: 4

Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma

Ji Eun Han, Hyo Jung Cho

Clin Mol Hepatol. 2024;30(2):160-163. Published online February 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0141

View: 3137 Download: 72

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang

Clin Mol Hepatol. 2024;30(2):150-153. Published online February 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0116

View: 4306 Download: 96 Web of Science: 5 Crossref: 5

Review

Recent advances in the management of hepatocellular carcinoma

Kamya Sankar, Jun Gong, Arsen Osipov, Steven A. Miles, Kambiz Kosari, Nicholas N. Nissen, Andrew E. Hendifar, Ekaterina K. Koltsova, Ju Dong Yang

Clin Mol Hepatol. 2024;30(1):1-15. Published online July 21, 2023

DOI: https://doi.org/10.3350/cmh.2023.0125

View: 10329 Download: 463 Web of Science: 60 Crossref: 57

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0360

View: 5370 Download: 145 Web of Science: 7 Crossref: 8

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease

Karim Seif El Dahan, Darine Daher, Amit G. Singal

Clin Mol Hepatol. 2023;29(Suppl):S207-S219. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0247

View: 9466 Download: 208 Web of Science: 17 Crossref: 19

Original Article

Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis

Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim

Clin Mol Hepatol. 2023;29(4):1013-1028. Published online July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0131

View: 5268 Download: 176 Web of Science: 5 Crossref: 5

Editorial

Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?

Hyo-Cheol Kim

Clin Mol Hepatol. 2023;29(4):984-986. Published online August 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0275

View: 2840 Download: 52

Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy

Sang Min Yoon

Clin Mol Hepatol. 2023;29(4):977-979. Published online August 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0336

View: 2716 Download: 51 Web of Science: 2 Crossref: 2

Review

Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma

Hwa Kyung Byun, Changhwan Kim, Jinsil Seong

Clin Mol Hepatol. 2023;29(4):945-957. Published online August 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0217

View: 4377 Download: 126 Web of Science: 10 Crossref: 13

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Viewed By 12260	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7275	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 6941	MAFLD: How is it different from NAFLD?
Viewed By 5587	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5375	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 348	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search